In October 2016, BD and Apax Partners established Vyaire Medical as a new global respiratory solutions company.
The move followed Apax’s acquisition of 50.1% stake in BD’s respiratory solutions business. BD owned 49.9% stake in the new company.
Based in Chicago, Vyaire Medical is engaged in the manufacturing and distribution of both respiratory and anesthesia/surgical consumables, as well as capital equipment for respiratory diagnostics and ventilation.
With around $800m annual sales, Vyaire Medical produces product under brands such as Bird, Bear, Jaeger, AirLife, Vital Signs, Viasys and others.
The company manufactures and markets over 27,000 products for the diagnosis, treatment and monitoring of respiratory conditions.
Subject to customary closing conditions, the deal is expected to be completed by the end of April.
Apax Partners partner Steven Dyson said: “A new senior management team led by CEO Dave Mowry has established key functions, delivered operational improvements, upgraded commercial capabilities and made two accretive acquisitions.
“It was on the basis of this progress, and the promise that we continue to see for the business, that we sought to acquire BD’s minority stake. We would like to thank the BD team for being excellent partners and supporting the company through its history.”
Vyaire president and CEO Dave Mowry said: “Vyaire Medical as a focused and leading global respiratory solutions provider with the objective of improving patient outcomes and increasing value for our customers.”
In October 2017, Vyaire Medical acquired US-based Revolutionary Medical Devices (RMD), which is engaged in the development of advanced products for airway management.
RMD’s SuperNO2VA is a complete noninvasive nasal PAP ventilation system, which will be used to treat respiratory insufficiency from collapse of the airway during or after sedation, or during the intubation process.
Image: Apax Partners to acquire remaining stake in respiratory solutions company Vyaire Medical. Photo: courtesy of Apax Partners.
